top of page

Pennsylvania Officials Warn About Federal Marijuana Policy That Could Jeopardize Health Funding

  • Writer: Bob Marley
    Bob Marley
  • Jun 21, 2021
  • 3 min read

Pennsylvania officials recently issued a memo stating that the federal government is withholding grant money for certain health programs that allow medical marijuana use among participants—but there is an exception.

In the bulletin posted this month, the state Department of Drug and Alcohol Programs said the federal Substance Abuse and Mental Health Services Administration (SAMHSA) “has been including the following special conditions in federal funding awards.”

Those conditions stipulate that grant funds “may not be used, directly or indirectly, to purchase, prescribe, or provide marijuana or treatment using marijuana.”

This decision, which also impacts grant funding for education programs, prompted a notice last year from Maine’s Education Department, which warned grant recipients about SAMHSA’s updated cannabis policy.

That said, a 2020 follow-up from the federal agency that was included in the new Pennsylvania notice adds some nuance to the policy. SAMHSA clarifies that recipients would only be disqualified from the grants if the people participating in their program are using marijuana for mental health or substance misuse treatment.

Further, it said that organizations would be able to continue receiving funding if patients use cannabis for those purposes so long as the clinician involved in their treatment documents the usage and the patient “is willing to work with the practitioner to understand the risks of the marijuana use and be willing to work toward using evidence-based alternatives to treat their mental/substance use disorder.”

But as far as advocates are concerned, the overall policy is convoluted, potentially preventing access to funding that could benefit whole communities simply because a given patient might be using cannabis in compliance with state laws.

What’s more, the effect of the ban could be arbitrary. What if, for example, a patient claimed that they were using medical marijuana to treat a pain condition when they could simultaneously be using it for undisclosed, mental health-related reasons? Then, theoretically, the grant funds would still be made available, contingent upon a non-disclosure.

But SAMHSA is insistent about the requirement in its memo.

The agency’s Q&A offers: “What if the patient is very clear about their wish to remain on their medical marijuana for their mental or substance use disorder—in this instance can the organization serve them?”

“No. The organization cannot serve a patient who is on medical marijuana for a mental or substance use disorder and wishes to remain on such treatment,” it says. “SAMHSA promotes the use of evidence-based practices and there is no evidence for such a treatment; in fact, there is increasing evidence that marijuana can further exacerbate mental health symptoms.”

“Further, SAMHSA believes the use of marijuana for these conditions in a treatment program designed to treat these conditions can compromise the therapeutic environment for those patients receiving services who wish to remain abstinent, use evidence-based treatment approaches and achieve recovery,” it continues.

“The practitioner should be very clear with the patient regarding the risk of being dismissed from the program if the patient chooses to remain on medical marijuana for mental/substance use disorder. If a patient is adamant about their desire to remain on medical marijuana for mental or SUDs despite the clinician’s efforts, the program should work with the patient to find an alternative non-SAMHSA funded program.”

After SAMHSA announced in 2019 that its marijuana policy would impact organizations applying for its two main opioid treatment program and another that provides funding to combat alcoholism and substance misuse, the Illinois Department of Human Services and Oregon Health Authority said the rule meant it would not beeligible forcertain grants.

Read the memo from Pennsylvania officials on the SAMHSA marijuana policy below: 

PA SAMHSA marijuana policy … by Marijuana Moment

Minnesota Marijuana Reform Could ‘Move Forward’ In Special Session That Just Launched, Top Lawmaker Says

Photo courtesy of Mike Latimer.

Recent Posts

See All

Comments


Global SEO Keywords

marihuana, cannabis, cáñamo, CBD, aceite de CBD, bálsamo de CBD, marijuana, hemp, weed, CBD oil, CBD balm, canapa, erba, olio di CBD, balsamo CBD, chanvre, herbe, huile de CBD, baume CBD, Marihuana, Cannabis, Hanf, Gras, CBD Öl, CBD Balsam, maconha, cânhamo, erva, óleo de CBD, bálsamo CBD, hennep, wiet, CBD olie, CBD balsem, hampa, gräs, CBD olja, CBD balsam, hamp, græs, gress, CBD olje, hamppu, ruoho, CBD öljy, CBD balsami, konopie, konopie indyjskie, olej CBD, balsam CBD, konopí, CBD olej, CBD balzám, konope, CBD balzam, marihuána, kannabisz, kender, fű, CBD olaj, CBD balzsam, canabis, cânepă, iarbă, ulei CBD, марихуана, канабис, коноп, CBD масло, CBD балсам, μαριχουάνα, κάνναβη, χασίς, λάδι CBD, βάλσαμο CBD, kanabis, konoplja, trava, CBD ulje, CBD olje, kanapės, kanapės indinės, CBD aliejus, CBD balzamas, marihuāna, kaņepes, CBD eļļa, CBD balzams, marihuaana, kanep, CBD õli, CBD palsam, kannabis, qanneb, żejt CBD, balsam CBD, marijúna, hampur, CBD olía, CBD smyrsl

Disclaimer

Jacob Hooy CBD Lip Balm is free from parabens and artificial colorants and contains no toxins or heavy metals, supporting natural body care. Our products are not intended to diagnose, treat, cure, or prevent any disease, medical condition, or symptom. The information provided on this website is for informational purposes only and must not be considered medical advice, nor a substitute for professional diagnosis, treatment, or guidance provided by qualified physicians, healthcare professionals, or pharmaceutical specialists. Nothing on this website should be interpreted as a recommendation, prescription, or therapeutic claim.

Difresh Spain is an online retail store registered under IAE Group 652.3, specializing in the retail trade of perfumery, cosmetic products, and personal hygiene and care items. NIF: Y3526859-F. E-mail: info@cbdvending.eu - WhatsApp: +34662918154 - Factory adress: Calle Albardín 13, Nave B07, 50720, La cartuja baja, Zaragoza, España. All prices include VAT and free shipping across all European Union countries.

© 2026 - www.cbdvending.euPrivacy Policy

bottom of page